Peripheral blood TCR marker of diffuse large B-cell lymphoma as well as detection kit and application of peripheral blood TCR marker

Abstract

The invention discloses a peripheral blood TCR marker of diffuse large B-cell lymphoma as well as a detection kit and application of the peripheral blood TCR marker. The marker comprises at least one of proteins of which the sequences are as shown in SEQ ID NO.1-100. On the basis of a high-throughput sequencing method, only a small amount of peripheral blood needs to be adopted, RNA is extracted, an immune map library is established by treating a sample, then through high-throughput sequencing and TCR data analysis, firstly, a characteristic TCR sequence in the peripheral blood of the diffuse large B-cell lymphoma is determined, and then a test result of a sample to be tested is compared with the characteristic TCR sequence, and therefore, whether the patient suffers from the diffuse large B-cell lymphoma or not is determined. According to the invention, a huge number of diffuse large B-cell lymphoma specific TCR sequences can be compared at the same time, and compared with single detection of one or more markers, the kit has higher specificity and accuracy, and the diagnosis efficiency is improved.

Description

technical field [0001] The invention belongs to the technical field of genetic engineering, and in particular relates to a diffuse large B-cell lymphoma peripheral blood TCR marker, a detection kit and application thereof. Background technique [0002] Non-Hodgkin Lymphoma (NHL) is a general term for a group of malignant tumors originating from lymph nodes and lymphoid tissues. NHL lesions mainly occur in lymph nodes, spleen, thymus and other lymph organs, and can also occur outside lymph nodes. Malignant neoplasms of lymphoid tissues and organs of the lymphohematopoietic system. According to the source of cells, it can be divided into three basic types: B cell, T cell and NK / T cell NHL. [0003] Epidemiology shows that there are relatively few patients with non-Hodgkin's lymphoma in my country, but the incidence has gradually increased in recent years. A recent survey shows that non-Hodgkin's lymphoma accounts for 4% of new tumors each year and 90% of all malignant lympho...

AI Technical Summary

Problems solved by technology

[0017] To sum up, blood tests in non-invasive examinations can only roughly determine the existence of diseases, and cannot distinguish specific diseases; bone marrow aspiration and biopsy in invasive examinations require biopsy, sampling is difficult, and cannot be used as a means of real-time monitoring. damage to the patient's body

It is often necessary to combine the results of blood and bone marrow aspiration tests, and the disease cannot be judged by one test, which also increases the burden on patients

Imaging detection also has its own advantages and disadvantages. Its detection requires the tumor to reach a certain size before it can be detected. There is a lag, and it cannot be used as a means of real-time monitoring due to radiation and other reasons.

Images